Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?

Short answer: I would.

Longer answer: We certainly know that STK11 mutations are associated with worse outcomes with immunotherapy. There are very few data sets and no large datasets that I am aware of that specifically look at this subset of patients with regard to chemoradiation followed by durvalu...